ArticleProceedings of the National Academy of Sciences of the United States of America2010
Lack of lacto/neolacto-glycolipids enhances the formation of glycolipid-enriched microdomains, facilitating B cell activation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Analysis of Lacto/Neolacto-Series Glycolipids and Gangliosides.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Multi-omics analysis of ST3GAL4-mediated lacto/neolacto glycosphingolipid metabolism reveals immune evasion and poor prognosis in TNBC.Frontiers in immunology · 2026Article
- B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer.iScience · 2024Article
- Impacts of β-1, 3-N-acetylglucosaminyltransferases (B3GNTs) in human diseases.Molecular biology reports · 2024Review
- Pan-cancer analysis of B3GNT5 with potential implications for cancer immunotherapy and cancer stem cell stemness.PloS one · 2024Article
- Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells.Oncogene · 2022Article
- Article
- B3GNT5 is a novel marker correlated with stem-like phenotype and poor clinical outcome in human gliomas.CNS neuroscience & therapeutics · 2020Article
- The Role of Glycosphingolipids in Immune Cell Functions.Frontiers in immunology · 2019Review
- Structure-based rationale for differential recognition of lacto- and neolacto- series glycosphingolipids by the N-terminal domain of human galectin-8.Scientific reports · 2016Article
- Synthesis of a novel photoactivatable glucosylceramide cross-linker.Journal of lipid research · 2016Article
- Helicobacter pylori chronic infection and mucosal inflammation switches the human gastric glycosylation pathways.Biochimica et biophysica acta · 2015Article
- Blood Groups in Infection and Host Susceptibility.Clinical microbiology reviews · 2015Review
- The consequences of genetic and pharmacologic reduction in sphingolipid synthesis.Journal of inherited metabolic disease · 2015Review
- Simplifying complexity: genetically resculpting glycosphingolipid synthesis pathways in mice to reveal function.Glycoconjugate journal · 2014Review
- High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients.Glycobiology · 2012Article
- The hypothesis on function of glycosphingolipids and ABO blood groups revisited.Neurochemical research · 2012Review
- Structural characterization of monosialo-, disialo- and trisialo-gangliosides by negative ion AP-MALDI-QIT-TOF mass spectrometry with MS(n) switching.Neurochemical research · 2012Article
- The role of lipid raft aggregation in the infection of type II pneumocytes by Mycobacterium tuberculosis.PloS one · 2012Article
- Strong antibody reaction against glycosphingolipids injected in liposome-embedded forms in beta3GN-T5 knockout mice.Nagoya journal of medical science · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a previous study, we demonstrated that beta1,3-N-acetylglucosaminyltransferase 5 (B3gnt5) is a lactotriaosylceramide (Lc(3)Cer) synthase that synthesizes a precursor structure for lacto/neolacto-series glycosphingolipids (GSLs) in in vitro experiments. Here, we generated B3gnt5-deficient (B3gnt5(-/-)) mice to investigate the in vivo biological functions of lacto/neolacto-series GSLs. In biochemical analyses, lacto/neolacto-series GSLs were confirmed to be absent and no Lc(3)Cer synthase activity was detected in the tissues of these mice. These results demonstrate that beta3GnT5 is the sole enzyme synthesizing Lc(3)Cer in vivo. Ganglioside GM1, known as a glycosphingolipid-enriched microdomain (GEM) marker, was found to be up-regulated in B3gnt5(-/-) B cells by flow cytometry and fluorescence microscopy. However, no difference in the amount of GM1 was observed by TLC-immunoblotting analysis. The GEM-stained puncta on the surface of B3gnt5(-/-) resting B cells were brighter and larger than those of WT cells. These results suggest that structural alteration of GEM occurs in B3gnt5(-/-) B cells. We next examined whether BCR signaling-related proteins, such as BCR, CD19, and the signaling molecule Lyn, had moved into or out of the GEM fraction. In B3gnt5(-/-) B cells, these molecules were enriched in the GEM fraction or adjacent fraction. Moreover, B3gnt5(-/-) B cells were more sensitive to the induction of intracellular phosphorylation signals on BCR stimulation and proliferated more vigorously than WT B cells. Together, these results suggest that lacto/neolacto-series GSLs play an important role in clustering of GEMs and tether-specific proteins, such as BCR, CD19, and related signaling molecules to the GEMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.